New hope for kids with devastating seizure disorders
NCT ID NCT05818553
Summary
This study is testing an investigational drug called PRAX-562 to see if it is safe and can help reduce seizures in children with rare, severe forms of epilepsy caused by specific genetic changes (SCN2A or SCN8A). Children in the study will first receive either the drug or a placebo for a period, followed by an option for all participants to receive the drug. The main goals are to measure changes in seizure frequency and monitor side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCN2A ENCEPHALOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Praxis Research Site
Atlanta, Georgia, 30329, United States
-
Praxis Research Site
Chicago, Illinois, 60611, United States
-
Praxis Research Site
Minneapolis, Minnesota, 55113, United States
-
Praxis Research Site
Hackensack, New Jersey, 07601, United States
-
Praxis Research Site
Tel Litwinsky, 52621, Israel
-
Praxis Research Site
Madrid, 28034, Spain
-
Praxis Research Site
Glasgow, G51 4TF, United Kingdom
-
Praxis Research Site
London, WC1N 3BH, United Kingdom
Conditions
Explore the condition pages connected to this study.